UY39479A - Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo - Google Patents
Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismoInfo
- Publication number
- UY39479A UY39479A UY0001039479A UY39479A UY39479A UY 39479 A UY39479 A UY 39479A UY 0001039479 A UY0001039479 A UY 0001039479A UY 39479 A UY39479 A UY 39479A UY 39479 A UY39479 A UY 39479A
- Authority
- UY
- Uruguay
- Prior art keywords
- preparing
- same
- benzimidazole
- procedure
- compound derived
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- -1 benzimidazole derivative compound Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se refiere a un comprimido de desintegración oral que incluye un compuesto derivado de benzimidazol y un procedimiento de preparación del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200138712 | 2020-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39479A true UY39479A (es) | 2021-11-30 |
Family
ID=79283599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039479A UY39479A (es) | 2020-10-23 | 2021-10-21 | Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230381109A1 (es) |
EP (1) | EP4232001A1 (es) |
JP (1) | JP2023547092A (es) |
KR (1) | KR20220054211A (es) |
CN (1) | CN116507318A (es) |
AR (1) | AR123872A1 (es) |
AU (1) | AU2021364255A1 (es) |
CA (1) | CA3196459A1 (es) |
MX (1) | MX2023004611A (es) |
UY (1) | UY39479A (es) |
WO (1) | WO2022086238A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3983269B1 (ja) * | 2003-09-03 | 2007-09-26 | ファイザー株式会社 | 5−ht4受容体作動活性を有するベンズイミダゾロン化合物 |
DE602006014996D1 (de) | 2005-12-19 | 2010-07-29 | Raqualia Pharma Inc | Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer |
US20090258897A1 (en) * | 2008-04-11 | 2009-10-15 | Auspex Pharmaceuticals, Inc. | Substituted benzimidazoles |
BRPI1013288A2 (pt) * | 2009-07-09 | 2016-03-29 | Raqualia Pharma Inc | uso de um composto, método de composição farmacêutica para o tratamento de doenças em que a motilidade gastrointestinal anormal está envolvida, kit e embalagem comercial que compreende uma composição farmacêutica contendo o composto |
KR101829706B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 산부가염 |
KR101960357B1 (ko) * | 2016-12-26 | 2019-03-20 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체를 포함하는 신규한 제제 |
CA3132575A1 (en) * | 2019-04-18 | 2020-10-22 | Thomas Julius Borody | Compositions and methods for treating, ameliorating and preventing h. pylori infections |
-
2021
- 2021-10-21 US US18/032,749 patent/US20230381109A1/en active Pending
- 2021-10-21 KR KR1020210141323A patent/KR20220054211A/ko not_active Application Discontinuation
- 2021-10-21 WO PCT/KR2021/014853 patent/WO2022086238A1/en active Application Filing
- 2021-10-21 UY UY0001039479A patent/UY39479A/es unknown
- 2021-10-21 EP EP21883306.9A patent/EP4232001A1/en active Pending
- 2021-10-21 JP JP2023524310A patent/JP2023547092A/ja active Pending
- 2021-10-21 CA CA3196459A patent/CA3196459A1/en active Pending
- 2021-10-21 AR ARP210102909A patent/AR123872A1/es unknown
- 2021-10-21 CN CN202180071926.8A patent/CN116507318A/zh active Pending
- 2021-10-21 AU AU2021364255A patent/AU2021364255A1/en active Pending
- 2021-10-21 MX MX2023004611A patent/MX2023004611A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023004611A (es) | 2023-05-08 |
CA3196459A1 (en) | 2022-04-28 |
AU2021364255A1 (en) | 2023-06-22 |
US20230381109A1 (en) | 2023-11-30 |
KR20220054211A (ko) | 2022-05-02 |
AR123872A1 (es) | 2023-01-18 |
JP2023547092A (ja) | 2023-11-09 |
EP4232001A1 (en) | 2023-08-30 |
CN116507318A (zh) | 2023-07-28 |
WO2022086238A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3806955T2 (ro) | Agoniști ai receptorului GLP-1 și utilizările acestora | |
CO2021003074A2 (es) | Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona y compuestos relacionados como inhibidores de ptpn11 (shp2) para el tratamiento del cáncer | |
ECSP21027049A (es) | Inhibidores de la proteína tirosina fosfatasa | |
MA43518A (fr) | 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase | |
CY1121107T1 (el) | Φαρμακοτεχνικες μορφες δισκιων αμεσης απελευθερωσης | |
CL2019003632A1 (es) | Síntesis de derivados fosfatos. | |
ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
CO2018008916A2 (es) | Compuestos de benzopirazol y análogos de estos | |
CO2017000363A2 (es) | Inhibidores de la desmetilasa-1 específica de la lisina (lsd-1) derivados del [(5-carbonil)-1h-pirrol-3-il]-benzonitrilo o [(4-carbonil)imidazol-2-il]-benzonitrilo | |
MX2018010191A (es) | Inhibidores de glucosidasa. | |
MX2020002841A (es) | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. | |
CL2019000573A1 (es) | Composiciones para comprimidos. | |
CL2018001541A1 (es) | Sintesis diastereoselectivo de derivados de fosfato y de profármaco gemcitabina nuc-1031. | |
MX2018008531A (es) | Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos. | |
MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
BR112017001758A2 (pt) | álcoois polivinílicos diretamente compressíveis | |
CO2017005498A2 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia | |
AR121624A2 (es) | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos | |
CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
CL2022001173A1 (es) | Forma cristalina de la base libre de un receptor del componente c5a del complemento | |
NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
EA201990198A1 (ru) | Радиолиганды для визуализации фермента ido1 | |
BR112017002859A2 (pt) | peça de sinterização, câmara de sinterização e programa de computador | |
UY39479A (es) | Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo |